APOTHEEK SIMOENS R.
ActiveSummary
APOTHEEK SIMOENS R. has been active since 1988 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €452,324 and a net result of €121,094. Equity has been growing by about 7.5% per year since 2019. Its solvency ranks better than 55% of 12,812 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Official details
Source: KBO- Status
- Active since 13-12-1988 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Pharmacies and pricing offices · annual accounts 31-03-2025
- Establishment unit
- 2.041.609.379 9620 Zottegem, since 21-12-1988
- Financial year end
- 31 March
- Peppol
- Reachable since 28-01-2026
Board and ownership
- BAELE NeleDirector · since 26-04-2023
- BAELE VeerleDirector · since 26-04-2023
- BALSIMMODirector · since 26-04-2023 · permanent representative SIMOENS Rosane Marie-Rose Ghislaine
- BALSIMMO99.2%· score 962025 annual accounts of BALSIMMO
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.2%
- Gross margin
- €433,126
- ▼ 7.9%
- Turnover
- ≈ €1.6m
- estimated
- Profit
- €121,094
- ▼ 29.8%
- Equity
- €452,324
- =
- Total assets
- €1.1m
- ▼ 9.8%
- Employees on 31-03-2025
- 2
- ▼ 33.3%
- 2026 accounts not filed, 5 days past the deadline
Score breakdownraises riskFigures for financial year 2025 (filed on 24-10-2025)lowers riskFounded in 1988Liquidity: current ratio 1.61, cash €276,812Size: 2.5 FTE, total assets €1.1mShow the evidence
Checked score
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 56% of them on solvency, 64% on liquidity, 75% on profitability and 39% on growth.
The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-03-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 6 accounts on average 12 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (1)
Key points
Recent changes
- · Gazette deed 3 directors appointed, 4 directors resigningResignations: SIMOENS Rosane Marie-Rose Ghislaine, BAELE Nele and 2 others · Appointments: BALSIMMO, BAELE Veerle and BAELE Nele · Director discharge: SIMOENS Rosane Marie-Rose Ghislaine
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as APOTHEEK SIMOENS R.: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1m and €1.3m, founded between 1982 and 1991.
| Company | Total assets | Gross margin |
|---|---|---|
| APOTHEEK SIMOENS R. Zottegem | €1.1m | €0.4m |
| FARDIL Dilbeek | €1.1m | €0.5m |
| DE BRABANDERE C. Waregem | €1.1m | €0.4m |
| APOTHEEK FRANSEN Hoogstraten | €1.0m | €0.4m |
| Apotheek De Belie Ghent | €1.2m | €0.5m |
| APOTHEEK HILDE D'HOOGHE Hamme (Vl.) | €1.0m | €0.5m |
| Apotheek VAN der ELST Filip Geraardsbergen | €1.3m | €0.5m |
Key facts about APOTHEEK SIMOENS R.
- What is the company number of APOTHEEK SIMOENS R.?
- The company number of APOTHEEK SIMOENS R. is 0436.024.502. The VAT number is the same number with BE in front: BE 0436.024.502.
- Where is APOTHEEK SIMOENS R. based?
- The registered office is at Ter Kameren 3, 9620 Zottegem.Company details
- What does APOTHEEK SIMOENS R. do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of APOTHEEK SIMOENS R.?
- APOTHEEK SIMOENS R. is a public limited company (NV).
- When was APOTHEEK SIMOENS R. founded?
- APOTHEEK SIMOENS R. was founded on 13-12-1988.
- Is APOTHEEK SIMOENS R. still active?
- Yes, APOTHEEK SIMOENS R. is an active enterprise in the KBO register.
- How many employees does APOTHEEK SIMOENS R. have?
- APOTHEEK SIMOENS R. had an average of 2.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does APOTHEEK SIMOENS R. fall under?
- In its 31-03-2025 annual accounts, APOTHEEK SIMOENS R. states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of APOTHEEK SIMOENS R.?
- The turnover in financial year 2025 is ≈ €1.6m. This figure is estimated from the gross margin of €433,126 and 47 comparable companies (NACE 477). It probably lies between €1.2m and €2.6m.
- Is APOTHEEK SIMOENS R. profitable?
- In financial year 2025, APOTHEEK SIMOENS R. made a profit of €121,094.
- Where can I find the annual accounts of APOTHEEK SIMOENS R.?
- APOTHEEK SIMOENS R. filed 36 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
Next steps
See how customers, suppliers and banks see your own company and what to improve first.